<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.4.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art540.dtd?><?SourceDTD.Version 5.4.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 2?><?origin publisher?><?FILEmeta_BBACLI89 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><front><journal-meta><journal-id journal-id-type="nlm-ta">BBA Clin</journal-id><journal-id journal-id-type="iso-abbrev">BBA Clin</journal-id><journal-title-group><journal-title>BBA Clinical</journal-title></journal-title-group><issn pub-type="epub">2214-6474</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4802402</article-id><article-id pub-id-type="publisher-id">S2214-6474(16)00003-9</article-id><article-id pub-id-type="doi">10.1016/j.bbacli.2015.12.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Up-regulation of the human-specific CHRFAM7A gene in inflammatory bowel disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baird</surname><given-names>Andrew</given-names></name><email>anbaird@ucsd.edu</email><xref rid="af0005" ref-type="aff">a</xref><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Coimbra</surname><given-names>Raul</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Xitong</given-names></name><xref rid="af0005" ref-type="aff">a</xref><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Eliceiri</surname><given-names>Brian P.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Costantini</surname><given-names>Todd W.</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib></contrib-group><aff id="af0005"><label>a</label>Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, USA</aff><aff id="af0010"><label>b</label>The Key Laboratory of Medical Electrophysiology, Institute of Cardiovascular Research, Sichuan Medical University, Luzhou, China</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author at: Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery, Department of Surgery, University of California San Diego, La Jolla, CA 98896, USA.Division of Trauma, Surgical Critical Care, Burns and Acute Care SurgeryDepartment of SurgeryUniversity of California San DiegoLa JollaCA98896USA <email>anbaird@ucsd.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>08</day><month>1</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>08</day><month>1</month><year>2016</year></pub-date><volume>5</volume><fpage>66</fpage><lpage>71</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2015</year></date><date date-type="rev-recd"><day>16</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>17</day><month>12</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2016 The Authors</copyright-statement><copyright-year>2016</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0005"><p>Background: The &#x003b1;7-subunit of the &#x003b1;7-nicotinic acetylcholine receptor (&#x003b1;7-nAChR) is an obligatory intermediate for the anti-inflammatory effects of the vagus nerve. But in humans, there exists a second gene called CHRFAM7A that encodes a dominant negative &#x003b1;7-nAChR inhibitor. Here, we investigated whether their expression was altered in inflammatory bowel disease (IBD) and colon cancer.</p><p>Methods: Quantitative RT-PCR measured gene expression of human &#x003b1;7-nAChR gene (CHRNA7), CHRFAM7A, TBC3D1, and actin in biopsies of normal large and small intestine, and compared to their expression in biopsies of ulcerative colitis, Crohn's disease, and colon cancer.</p><p>Results: qRT-PCR showed that CHRFAM7A and CHRNA7 gene expression was significantly (p&#x000a0;&#x0003c;&#x000a0;.02) up-regulated in IBD (N&#x000a0;=&#x000a0;64). Gene expression was unchanged in colon cancer. Further analyses revealed that there were differences in ulcerative colitis and Crohn's Disease. Colon biopsies of ulcerative colitis (N&#x000a0;=&#x000a0;33) confirmed increased expression of CHRFAM7A and decreased in CHRNA7 expression (p&#x000a0;&#x0003c;&#x000a0;0.001). Biopsies of Crohn's disease (N&#x000a0;=&#x000a0;31), however, showed only small changes in CHRFAM7A expression (p&#x000a0;&#x0003c;&#x000a0;0.04) and no change in CHRNA7. When segregated by tissue source, both CHRFAM7A up-regulation (p&#x000a0;&#x0003c;&#x000a0;0.02) and CHRNA7 down-regulation (p&#x000a0;&#x0003c;&#x000a0;0.001) were measured in colon, but not in small intestine.</p><p>Conclusion: The human-specific CHRFAM7A gene is up-regulated, and its target, CHRNA7, down-regulated, in IBD. Differences between ulcerative colitis and Crohn's disease tie to location of disease.</p><p>Significance: The appearance of IBD in modern humans may be consequent to the emergence of CHRFAM7A, a human-specific &#x003b1;7-nAChR antagonist. CHRFAM7A could present a new, unrecognized target for development of IBD therapeutics.</p></abstract><abstract abstract-type="author-highlights" id="ab0010"><title>Highlights</title><p><list list-type="simple"><list-item id="u0005"><label>&#x02022;</label><p>CHRFAM7A is a pro-inflammatory and human-specific gene not found in other species.</p></list-item><list-item id="u0010"><label>&#x02022;</label><p>CHRFAM7A expression is elevated in certain IBD, but its target CHRNA7 decreased.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p>Changes in CHRFAM7A and CHRNA7 expression are disease- and tissue site specific.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p>Some IBDs may be examples of &#x0201c;off-target disease sequelae&#x0201d; of human evolution.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p>Animal modeling of human disease do not test contributions of human-specific genes.</p></list-item></list></p></abstract></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p>The emergence of human-specific genes (HSG) in the course of human evolution are presumed to have enabled the adaptation of humans to new environments and new behaviors <xref rid="bb0005" ref-type="bibr">[1]</xref>, <xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>, <xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>, <xref rid="bb0045" ref-type="bibr">[9]</xref> but their specific physiological functions are often unknown. The human-specific CHRFAM7A gene is a case in point. First, it encodes a uniquely human and independently regulated subunit of the &#x003b1;7-nicotinic acetylcholine receptor (&#x003b1;7-nAChR) that regulates neurotransmitter function. Therefore, it is presumed to affect CNS function. When co-expressed with &#x003b1;7-nAChR, however, CHRFAM7A is a dominant negative regulator of neurotransmitter binding to, and activation of, the &#x003b1;7-nAChR, thereby potentially altering the central nervous system functions of &#x003b1;7-nAChR in its regulation of processes like cognition, memory, and mental health <xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>, <xref rid="bb0065" ref-type="bibr">[13]</xref>, <xref rid="bb0070" ref-type="bibr">[14]</xref>, <xref rid="bb0075" ref-type="bibr">[15]</xref>, <xref rid="bb0080" ref-type="bibr">[16]</xref>, <xref rid="bb0085" ref-type="bibr">[17]</xref>, <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>.</p><p>But CHRFAM7A is also widely expressed in leukocytes and epithelial cells <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref>, where it is presumed to regulate the powerful anti-inflammatory effects of &#x003b1;7-nAChR activation <xref rid="bb0110" ref-type="bibr">[22]</xref>, <xref rid="bb0115" ref-type="bibr">[23]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>. Because the activation of &#x003b1;7-nAChR is an obligatory intermediate for vagus nerve control of inflammation <xref rid="bb0125" ref-type="bibr">[25]</xref>, CHRFAM7A in humans must therefore regulate the anti-inflammatory vagus nerve. If so, it raises the possibility that CHRFAM7A expression in peripheral tissues <xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref> could be associated with human inflammatory disease like, for example, inflammatory bowel disease (IBDs).</p><p>IBDs have complex molecular etiologies of genetic, epigenetic, microbial, and environmental origin that present as highly heterogeneous episodes of gut inflammation <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>, making animal modeling difficult <xref rid="bb0140" ref-type="bibr">[28]</xref>. Accordingly, the response of IBDs to behavioral, dietary, and therapeutic interventions is often enigmatic, as exemplified by both protective and deleterious effects of nicotine and nicotine withdrawal on its remission, recurrence, and treatment <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>. Here, we explored the possibility that a concomitant, but differentially regulated <xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref> expression of the human-specific and pro-inflammatory CHRFAM7A gene and its anti-inflammatory &#x003b1;7-nAChR target <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>, <xref rid="bb0125" ref-type="bibr">[25]</xref> (CHRNA7), could be implicated in IBD.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Biopsies of inflammatory bowel disease and colon cancer</title><p>cDNAs in OriGene TissueScan Arrays from characterized biopsies of ulcerative colitis (CCRT101 and CCRT 102), Crohn's disease (CCRT101 and CCRT 102), or colon cancer (HCRT104) were used to assess gene expression in disease (N&#x000a0;=&#x000a0;109) and control (N&#x000a0;=&#x000a0;19) tissue biopsies. All characteristics of these specimens are available online with detailed clinical information, histology slides of each biopsy, and the quality control data for RNA isolation and cDNA preparations at California <ext-link ext-link-type="uri" xlink:href="http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx" id="ir0005">http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx</ext-link>. The original de-identified tissues were collected from accredited medical institutions in the United States using IRB-approved protocols, selected by board-certified pathologists and then deposited into the OriGene tissue biorepository along with all of the available clinical data supporting the pathology diagnoses. The specific array plates used contained cDNA synthesized prepared from RNA extracted from these pathologist-verified tissues. The quantity of cDNA was normalized, first validated with &#x000df;-actin at OriGene and the findings replicated in the course of the gene expression studies described here. The Ct value of actin gene expression in each well was determined in our laboratories was highly consistent (average 20.89&#x000a0;cycles&#x000a0;&#x000b1;&#x000a0;0.1 (SEM, N&#x000a0;=&#x000a0;135)) and the individual values from each well used to calculate relative gene expression in each biopsy using the actin primers, as specifically noted by the array manufacturer.</p></sec><sec id="s0020"><label>2.2</label><title>PCR, primers, and the conditions for CHRFAM7A, CHRNA7, and TBC1D3 analyses</title><p>The PCR reaction was performed in 50&#x000a0;&#x003bc;l containing 45&#x000a0;&#x003bc;l PCR blue mix (Invitrogen), 1&#x000a0;&#x003bc;l of each primer (10&#x000a0;&#x003bc;M), 300&#x000a0;ng cDNA, and 2&#x000a0;&#x003bc;l water. The cycling conditions were 94&#x000a0;&#x000b0;C for 4&#x000a0;min followed by 35&#x000a0;cycles of 94&#x000a0;&#x000b0;C for 30&#x000a0;s, 60&#x000a0;&#x000b0;C for 30&#x000a0;s, and 72&#x000a0;&#x000b0;C for 60&#x000a0;s, and a final extension at 72&#x000a0;&#x000b0;C for 5&#x000a0;min. Ten microliters of each PCR product was resolved on a 2% agarose gel and images were acquired using Alpha Innotech imaging system. Real-time qPCR was performed in a 25&#x000a0;&#x003bc;l reaction containing 12.5&#x000a0;&#x003bc;l 2&#x000a0;&#x000d7; CYBR Green PCR Master Mix (BioRad), 0.5&#x000a0;&#x003bc;l of each primer (10&#x000a0;&#x003bc;M), 1&#x000a0;&#x003bc;l cDNA, and 10.5&#x000a0;&#x003bc;l water. PCR cycling conditions were 95&#x000a0;&#x000b0;C for 10&#x000a0;min followed by 45&#x000a0;cycles of 94&#x000a0;&#x000b0;C for 25&#x000a0;s, 60&#x000a0;&#x000b0;C for 25&#x000a0;s, and 72&#x000a0;&#x000b0;C for 40&#x000a0;s. Primer efficiency for CHRFAM7A and CHRNA7 were 100% and 94%, respectively.</p><p>Expression of CHRNA7 and CHRFAM7A was normalized to that of &#x003b2;-actin using &#x00394;&#x00394;Ct method and primers provided by the manufacturer of tissue arrays. Primers for CHRFAM7A were designed to hybridize with the variant 1 transcript by selecting oligonucleotide sequences bridging shared CHRFAM7A and CHRNA7 sequences and therefore unique to CHRFAM7A and not available in CHRFAM7A or CHRNA7A alone.<table-wrap id="t0010" position="float"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Sense:</td><td align="left">5&#x02032;-ATAGCTGCAAACTGCGATA-3&#x02032;,</td></tr><tr><td align="left">Anti-sense:</td><td align="left">5&#x02032;-CAGCGTACATCGATGTAGCAG-3&#x02032;</td></tr></tbody></table></table-wrap></p><p>Primers for CHRNA7 were designed to hybridize with both variant 1 and 2 transcripts of human CHRNA7 by selecting oligonucleotide sequences that are present in both variants of human CHRNA7 but absent from CHRFAM7A.<table-wrap id="t0015" position="float"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Sense:</td><td align="left">5&#x02032;-ACATGCGCTGCTCGCCGGGA-3&#x02032;,</td></tr><tr><td align="left">Anti-sense:</td><td align="left">5&#x02032;-GATTGTAGTTCTTGACCAGCT-3&#x02032;.</td></tr></tbody></table></table-wrap></p><p>Primers for TBC1D3 were selected based on previously published findings <xref rid="bb0145" ref-type="bibr">[29]</xref>:<table-wrap id="t0020" position="float"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Sense:</td><td align="left">5&#x02032;-GCATCGACCGGGACGTAAG-3&#x02032;,</td></tr><tr><td align="left">Anti-sense:</td><td align="left">5&#x02032;-CCTCCGGGTTGTACTCCTCAT-3&#x02032;.</td></tr></tbody></table></table-wrap></p></sec><sec id="s0025"><label>2.3</label><title>Analyses of gene expression</title><p>CHRFAM7A, CHRNA7, TBC1D3, and actin gene expression were measured as described above and normalized to that of &#x003b2;-actin or as indicated, to CHRNA7 expression, in each sample. The fold change in gene expression was calculated by &#x00394;&#x00394;Ct method and analyzed using the relative expression software tool (REST) for group-wise comparisons of relative expression <xref rid="bb0150" ref-type="bibr">[30]</xref>. The GraphPad program PRISM6 was used for preparation of figures.</p></sec></sec><sec id="s0030"><label>3</label><title>Results and discussion</title><p>The characteristics of the commercially available gene expression arrays of human IBD and colon cancer used in these studies are publicly available <ext-link ext-link-type="uri" xlink:href="http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx" id="ir0010">http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx</ext-link> and include information regarding gender, age, tissue of origin, case diagnosis from donor institutions, histological sections, and pathology verification reports. The latter also includes the percentage of mucosa/differentiation, lesion, and inflammation and are summarized in <xref rid="t0005" ref-type="table">Table 1</xref>.</p><sec id="s0035"><label>3.1</label><title>CHRFAM7A and the gene encoding human &#x003b1;7-nAChR (CHRNA7) are differentially expressed in IBD</title><p>Initially, quantitative RT-PCR of biopsies (N&#x000a0;=&#x000a0;64) from patients with IBD suggested that there was only a small, albeit significant (p&#x000a0;&#x0003c;&#x000a0;0.05) increase in CHRFAM7A gene expression (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>A</italic>) compared to biopsies from control tissue. In cDNA prepared from these same biopsies, there was no significant difference in CHRNA7 gene expression (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>B</italic>) although the ratio of CHRFAM7A/CHRNA7 gene expression (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>C</italic>) was different in IBD (p&#x000a0;&#x0003c;&#x000a0;0.02) compared with controls.</p><p>In contrast, when we compared CHRFAM7A and CHRNA7 gene expression in the two distinct forms of disease represented in IBD (ulcerative colitis and Crohn's disease), a significant pattern emerged. First, colon biopsies from patients with ulcerative colitis (N&#x000a0;=&#x000a0;33) confirmed the global increase in expression of CHRFAM7A (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>D</italic>), but now the analyses revealed that there was a concomitant and significant (p&#x000a0;&#x0003c;&#x000a0;0.001) decrease in CHRNA7 expression in ulcerative colitis (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>E</italic>). These changes in ulcerative colitis were also highly significant (p&#x000a0;&#x0003c;&#x000a0;0.001) when comparing CHRNA7 expression to that of CHRFAM7A (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>F</italic>). In Crohn's disease (N&#x000a0;=&#x000a0;31), there was a small but significant (p&#x000a0;&#x0003c;&#x000a0;0.04) increase in CHRFAM7A gene expression (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>G</italic>) but no significant change in CHRNA7 expression (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>H</italic>). As earlier, normalization of CHRFAM7A with CHRNA7 expression increased the significance of the difference (p&#x000a0;&#x0003c;&#x000a0;0.02, <xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>I</italic>).</p><p>Ulcerative colitis affects colon and not small intestine but Crohn's disease can affect any portion of the gastrointestinal tract <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>. In analyzing the source of biopsy <bold>(</bold><xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>J</italic>, <italic>K</italic>, and <italic>L</italic>), we observed a significant (p&#x000a0;&#x0003c;&#x000a0;0.02) up-regulation in CHRFAM7A gene expression in colon from patients with Crohn's disease (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>J</italic>), but there was also a concomitant and significant (p&#x000a0;&#x0003c;&#x000a0;0.001) down-regulation in CHRNA7 (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>K</italic>) underscored by the significant change of CHRFAM7A when normalized with CHRNA7 (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>K</italic>). In small intestine biopsies of Crohn's disease, the change in CHRFAM7A (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>M</italic>), CHRNA7 (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>N</italic>) or in the ratio of CHRFAM7A to CHRNA7 (Fig. 10) was not significant.</p></sec><sec id="s0040"><label>3.2</label><title>The changes in CHRFAM7A and CHRNA7 are specific</title><p>We used two approaches to establish specificity of differential expression in diseased colon. First, we evaluated the expression of CHRFAM7A (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>A</italic> and <italic>D</italic>), CHRNA7 (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B</italic> and <italic>E</italic>), and CHRFAM7A-to-CHRNA7 ratio (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>C</italic> and <italic>F</italic>) in colon cancer biopsies. No differences were detected when all colon cancer biopsies were evaluated together (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>A</italic>, <italic>B</italic>, <italic>C</italic>) or when analyzed according to the stage of disease (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>D</italic>, <italic>E</italic>, F). Second, we evaluated the expression of a second human-specific gene called TBC1D3, that is associated with macro-pinocytosis and epidermal growth factor signaling <xref rid="bb0145" ref-type="bibr">[29]</xref>. There were no differences in IBD, no differences in either ulcerative colitis or Crohn's disease when examined separately. There were also no differences in gene expression of TBC1D3 in biopsies from colon cancer (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>G</italic>, <italic>H</italic>, <italic>I</italic>). This concordance of CHRFAM7A and CHRNA7 expression in colon cancer is also evident in curated public databases like the Cancer Genome Atlas (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org" id="ir0015">www.cbioportal.org</ext-link>), which enables mining gene expression patterns in different epithelial cancers. Correlations between CHRFAM7A and CHRNA7 in these databases are &#x0003e;&#x000a0;0.87 (Pearson) and &#x0003e;&#x000a0;0.77 (Spearman) in uterine, stomach, and colorectal cancers). Unfortunately, no analogous public databases with RNAseq data exist for inflammatory bowel disease, Crohn's disease, or ulcerative colitis, although several studies have evaluated whole genome gene expression <xref rid="bb0155" ref-type="bibr">[31]</xref>, <xref rid="bb0160" ref-type="bibr">[32]</xref>, <xref rid="bb0165" ref-type="bibr">[33]</xref> and found changes in, and effects of, traditional inflammatory products like TNF and HMBG1 <xref rid="bb0170" ref-type="bibr">[34]</xref>, <xref rid="bb0175" ref-type="bibr">[35]</xref>.</p><p>In 2011, Cooper and Kehrer-Sawatzki <xref rid="bb0040" ref-type="bibr">[8]</xref> reported that new human genes <xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>, <xref rid="bb0045" ref-type="bibr">[9]</xref> are over-represented among genes tied to complex human disease and more recently <xref rid="bb0180" ref-type="bibr">[36]</xref> described how newly evolved human genes can drive gene interaction networks associated with critical phenotypes. It is in this vein that the results presented here suggest that the up-regulation of pro-inflammatory CHRFAM7A in humans could exacerbate the down-regulation of anti-inflammatory &#x003b1;7-nAChR in IBD. If so, it is interesting to speculate that this pro-inflammatory effect of CHRFAM7A expression is an &#x0201c;off-target&#x0201d; contributor to human IBD that arose as a function of adaptation (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>J</italic>, <italic>K</italic>). In this paradigm, a human-specific gene like CHRFAM7A could have originally arisen as an evolutionary pro-inflammatory and adaptative response to newly emerging human behaviors like bipedal walking (trauma) or the harnessing of fire (burn injury) but retained for CNS activities regulating neurotransmitter activity. Interestingly, human-specific responses in gene expression after trauma, burn, and infection have been previously described <xref rid="bb0185" ref-type="bibr">[37]</xref>, although they remain controversial largely because of their implications to animal modeling of human injury <xref rid="bb0190" ref-type="bibr">[38]</xref>, <xref rid="bb0195" ref-type="bibr">[39]</xref>. Ironically, the putative adaptive pro-inflammatory origin of a hominid gene like CHRFAM7A may ultimately be ancillary to its physiological significance to human speciation because CHRFAM7A in the brain is tied to regulating &#x003b1;7-nAChR, a ligand-gated neurotransmitter channel that itself regulates human cognition, attention, memory, and mental health. In this model, the up-regulation of CHRFAM7A in peripheral tissues of modern humans could reflect vestigial pro-inflammatory activity. Such a possible paradigm underscores the importance of understanding the role of human evolution in the etiology of human disease, the role of HSGs, and ultimately, their function when modeling human disease.</p><p>On a final note, the differential expression of the CHRFAM7A human-specific gene in a prototypic human disease like IBD underscores the importance of better understanding the contribution of this class of genes to the onset, development, and progression human disease when diseases are modeled in experimental animals. With newly emerged human-specific genes like ARHGAP11B promoting neocortex expansion <italic>in vivo</italic>
<xref rid="bb0200" ref-type="bibr">[40]</xref>, c20orf203 eliciting differential gene function <xref rid="bb0205" ref-type="bibr">[41]</xref>, human-specific defensins conferring differential resistance to infection <xref rid="bb0210" ref-type="bibr">[42]</xref>, and CD33 providing cognitive protection <xref rid="bb0215" ref-type="bibr">[43]</xref>, it is critical to understand the possible contributions of newly evolved gene interaction networks to human disease when they differ in humans from all other species and create unique phenotypes <xref rid="bb0180" ref-type="bibr">[36]</xref>.</p></sec></sec><sec id="s0045"><title>Author contributions</title><p>Conceived of experiments and wrote first drafts of manuscript (AB), designed PCR and validated qPCR (XD), assisted in interpretation of data and assisted in preparation of brief report (RC, BE, and TC).</p></sec><sec id="s0050"><title>Conflict of interest statement</title><p>The authors have declared that no conflict of interest exists.</p></sec></body><back><ref-list><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Mitra</surname><given-names>N.</given-names></name><name><surname>Secundino</surname><given-names>I.</given-names></name><name><surname>Banda</surname><given-names>K.</given-names></name><name><surname>Cruz</surname><given-names>P.</given-names></name><name><surname>Padler-Karavani</surname><given-names>V.</given-names></name><name><surname>Verhagen</surname><given-names>A.</given-names></name><name><surname>Reid</surname><given-names>C.</given-names></name><name><surname>Lari</surname><given-names>M.</given-names></name><name><surname>Rizzi</surname><given-names>E.</given-names></name></person-group><article-title>Specific inactivation of two immunomodulatory SIGLEC genes during human evolution</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>109</volume><year>2012</year><fpage>9935</fpage><lpage>9940</lpage><pub-id pub-id-type="pmid">22665810</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Krinsky</surname><given-names>B.H.</given-names></name><name><surname>Long</surname><given-names>M.</given-names></name></person-group><article-title>New genes as drivers of phenotypic evolution</article-title><source>Nat. Rev. Genet.</source><volume>14</volume><year>2013</year><fpage>645</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">23949544</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Long</surname><given-names>M.</given-names></name><name><surname>VanKuren</surname><given-names>N.W.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Vibranovski</surname><given-names>M.D.</given-names></name></person-group><article-title>New gene evolution: little did we know</article-title><source>Annu. Rev. Genet.</source><volume>47</volume><year>2013</year><fpage>307</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">24050177</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>N.G.</given-names></name><name><surname>Eyre-Walker</surname><given-names>A.</given-names></name></person-group><article-title>Human disease genes: patterns and predictions</article-title><source>Gene</source><volume>318</volume><year>2003</year><fpage>169</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">14585509</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Tautz</surname><given-names>D.</given-names></name><name><surname>Domazet-Loso</surname><given-names>T.</given-names></name></person-group><article-title>The evolutionary origin of orphan genes</article-title><source>Nat. Rev. Genet.</source><volume>12</volume><year>2011</year><fpage>692</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">21878963</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Varki</surname><given-names>A.</given-names></name><name><surname>Altheide</surname><given-names>T.K.</given-names></name></person-group><article-title>Comparing the human and chimpanzee genomes: searching for needles in a haystack</article-title><source>Genome Res.</source><volume>15</volume><year>2005</year><fpage>1746</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">16339373</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="book" id="rf0035"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.E.</given-names></name><name><surname>Landback</surname><given-names>P.</given-names></name><name><surname>Vibranovski</surname><given-names>M.</given-names></name><name><surname>Long</surname><given-names>M.</given-names></name></person-group><chapter-title>New genes expressed in human brains: implications for annotating evolving genomes</chapter-title><series>BioEssays: news and reviews in molecular, cellular and developmental biology</series><volume>34</volume><year>2012</year><fpage>982</fpage><lpage>991</lpage></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>D.N.</given-names></name><name><surname>Kehrer-Sawatzki</surname><given-names>H.</given-names></name></person-group><article-title>Exploring the potential relevance of human-specific genes to complex disease</article-title><source>Hum. Genet.</source><volume>5</volume><year>2011</year><fpage>99</fpage><lpage>107</lpage></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>H.</given-names></name><name><surname>Winter</surname><given-names>E.E.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Weinstock</surname><given-names>K.G.</given-names></name><name><surname>Xing</surname><given-names>H.</given-names></name><name><surname>Goodstadt</surname><given-names>L.</given-names></name><name><surname>Stenson</surname><given-names>P.D.</given-names></name><name><surname>Cooper</surname><given-names>D.N.</given-names></name><name><surname>Smith</surname><given-names>D.</given-names></name><name><surname>Alba</surname><given-names>M.M.</given-names></name></person-group><article-title>Evolutionary conservation and selection of human disease gene orthologs in the rat and mouse genomes</article-title><source>Genome Biol.</source><volume>5</volume><year>2004</year><fpage>R47</fpage><pub-id pub-id-type="pmid">15239832</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Bacchelli</surname><given-names>E.</given-names></name><name><surname>Battaglia</surname><given-names>A.</given-names></name><name><surname>Cameli</surname><given-names>C.</given-names></name><name><surname>Lomartire</surname><given-names>S.</given-names></name><name><surname>Tancredi</surname><given-names>R.</given-names></name><name><surname>Thomson</surname><given-names>S.</given-names></name><name><surname>Sutcliffe</surname><given-names>J.S.</given-names></name><name><surname>Maestrini</surname><given-names>E.</given-names></name></person-group><article-title>Analysis of CHRNA7 rare variants in autism spectrum disorder susceptibility</article-title><source>Am. J. Med. Genet. A</source><year>2015</year></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>T.W.</given-names></name><name><surname>Dang</surname><given-names>X.</given-names></name><name><surname>Coimbra</surname><given-names>R.</given-names></name><name><surname>Eliceiri</surname><given-names>B.P.</given-names></name><name><surname>Baird</surname><given-names>A.</given-names></name></person-group><article-title>CHRFAM7A, a human-specific and partially duplicated alpha7-nicotinic acetylcholine receptor gene with the potential to specify a human-specific inflammatory response to injury</article-title><source>J. Leukoc. Biol.</source><volume>97</volume><year>2015</year><fpage>247</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">25473097</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>De Luca</surname><given-names>V.</given-names></name><name><surname>Likhodi</surname><given-names>O.</given-names></name><name><surname>Van Tol</surname><given-names>H.H.</given-names></name><name><surname>Kennedy</surname><given-names>J.L.</given-names></name><name><surname>Wong</surname><given-names>A.H.</given-names></name></person-group><article-title>Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia</article-title><source>Acta Psychiatr. Scand.</source><volume>114</volume><year>2006</year><fpage>211</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">16889592</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>E.L.</given-names></name><name><surname>Toulopoulou</surname><given-names>T.</given-names></name><name><surname>McDonald</surname><given-names>C.</given-names></name><name><surname>Bramon</surname><given-names>E.</given-names></name><name><surname>Walshe</surname><given-names>M.</given-names></name><name><surname>Wickham</surname><given-names>H.</given-names></name><name><surname>Sham</surname><given-names>P.C.</given-names></name><name><surname>Murray</surname><given-names>R.M.</given-names></name><name><surname>Collier</surname><given-names>D.A.</given-names></name></person-group><article-title>Episodic memory performance predicted by the 2&#x000a0;bp deletion in exon 6 of the &#x0201c;alpha 7-like&#x0201d; nicotinic receptor subunit gene</article-title><source>Am. J. Psychiatry</source><volume>163</volume><year>2006</year><fpage>1832</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">17012698</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Flomen</surname><given-names>R.H.</given-names></name><name><surname>Collier</surname><given-names>D.A.</given-names></name><name><surname>Osborne</surname><given-names>S.</given-names></name><name><surname>Munro</surname><given-names>J.</given-names></name><name><surname>Breen</surname><given-names>G.</given-names></name><name><surname>St Clair</surname><given-names>D.</given-names></name><name><surname>Makoff</surname><given-names>A.J.</given-names></name></person-group><article-title>Association study of CHRFAM7A copy number and 2&#x000a0;bp deletion polymorphisms with schizophrenia and bipolar affective disorder</article-title><source>Am. J. Med. Genet. B Neuropsychiatr. Genet.</source><volume>141B</volume><year>2006</year><fpage>571</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">16823804</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Gault</surname><given-names>J.</given-names></name><name><surname>Hopkins</surname><given-names>J.</given-names></name><name><surname>Berger</surname><given-names>R.</given-names></name><name><surname>Drebing</surname><given-names>C.</given-names></name><name><surname>Logel</surname><given-names>J.</given-names></name><name><surname>Walton</surname><given-names>C.</given-names></name><name><surname>Short</surname><given-names>M.</given-names></name><name><surname>Vianzon</surname><given-names>R.</given-names></name><name><surname>Olincy</surname><given-names>A.</given-names></name><name><surname>Ross</surname><given-names>R.G.</given-names></name></person-group><article-title>Comparison of polymorphisms in the alpha7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects</article-title><source>Am. J. Med. Genet. B Neuropsychiatr. Genet.</source><volume>123B</volume><year>2003</year><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">14582144</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>C.J.</given-names></name><name><surname>Lai</surname><given-names>I.C.</given-names></name><name><surname>Liou</surname><given-names>L.L.</given-names></name><name><surname>Tsai</surname><given-names>S.J.</given-names></name></person-group><article-title>Association study of the human partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant with bipolar disorder</article-title><source>Neurosci. Lett.</source><volume>355</volume><year>2004</year><fpage>69</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">14729237</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Neri</surname><given-names>M.</given-names></name><name><surname>Bonassi</surname><given-names>S.</given-names></name><name><surname>Russo</surname><given-names>P.</given-names></name></person-group><article-title>Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia</article-title><source>Curr. Drug Targets</source><volume>13</volume><year>2012</year><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">22300029</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Petrovsky</surname><given-names>N.</given-names></name><name><surname>Schmechtig</surname><given-names>A.</given-names></name><name><surname>Flomen</surname><given-names>R.H.</given-names></name><name><surname>Kumari</surname><given-names>V.</given-names></name><name><surname>Collier</surname><given-names>D.</given-names></name><name><surname>Makoff</surname><given-names>A.</given-names></name><name><surname>Wagner</surname><given-names>M.</given-names></name><name><surname>Ettinger</surname><given-names>U.</given-names></name></person-group><article-title>CHRFAM7A copy number and 2-bp deletion polymorphisms and antisaccade performance</article-title><source>Int. J. Neuropsychopharmacol.</source><volume>12</volume><year>2009</year><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">19149910</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Sinkus</surname><given-names>M.L.</given-names></name><name><surname>Graw</surname><given-names>S.</given-names></name><name><surname>Freedman</surname><given-names>R.</given-names></name><name><surname>Ross</surname><given-names>R.G.</given-names></name><name><surname>Lester</surname><given-names>H.A.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name></person-group><article-title>The human CHRNA7 and CHRFAM7A genes: a review of the genetics, regulation, and function</article-title><source>Neuropharmacology</source><year>2015</year></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Costantini</surname><given-names>T.W.</given-names></name><name><surname>Dang</surname><given-names>X.</given-names></name><name><surname>Yurchyshyna</surname><given-names>M.V.</given-names></name><name><surname>Coimbra</surname><given-names>R.</given-names></name><name><surname>Eliceiri</surname><given-names>B.P.</given-names></name><name><surname>Baird</surname><given-names>A.</given-names></name></person-group><article-title>A human-specific alpha7-nicotinic acetylcholine receptor gene in human leukocytes: identification, regulation and the consequences of CHRFAM7A expression</article-title><source>Mol. Med.</source><year>2015</year></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>X.</given-names></name><name><surname>Eliceiri</surname><given-names>B.P.</given-names></name><name><surname>Baird</surname><given-names>A.</given-names></name><name><surname>Costantini</surname><given-names>T.W.</given-names></name></person-group><article-title>CHRFAM7A: a human-specific alpha7-nicotinic acetylcholine receptor gene shows differential responsiveness of human intestinal epithelial cells to LPS</article-title><source>FASEB J.</source><year>2015</year></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Araud</surname><given-names>T.</given-names></name><name><surname>Graw</surname><given-names>S.</given-names></name><name><surname>Berger</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>M.</given-names></name><name><surname>Neveu</surname><given-names>E.</given-names></name><name><surname>Bertrand</surname><given-names>D.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name></person-group><article-title>The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of alpha7*nAChR function</article-title><source>Biochem. Pharmacol.</source><volume>82</volume><year>2011</year><fpage>904</fpage><lpage>914</lpage><pub-id pub-id-type="pmid">21718690</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>de Lucas-Cerrillo</surname><given-names>A.M.</given-names></name><name><surname>Maldifassi</surname><given-names>M.C.</given-names></name><name><surname>Arnalich</surname><given-names>F.</given-names></name><name><surname>Renart</surname><given-names>J.</given-names></name><name><surname>Atienza</surname><given-names>G.</given-names></name><name><surname>Serantes</surname><given-names>R.</given-names></name><name><surname>Cruces</surname><given-names>J.</given-names></name><name><surname>Sanchez-Pacheco</surname><given-names>A.</given-names></name><name><surname>Andres-Mateos</surname><given-names>E.</given-names></name><name><surname>Montiel</surname><given-names>C.</given-names></name></person-group><article-title>Function of partially duplicated human alpha77 nicotinic receptor subunit CHRFAM7A gene: potential implications for the cholinergic anti-inflammatory response</article-title><source>J. Biol. Chem.</source><volume>286</volume><year>2011</year><fpage>594</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">21047781</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Indersmitten</surname><given-names>T.</given-names></name><name><surname>Freedman</surname><given-names>R.</given-names></name><name><surname>Leonard</surname><given-names>S.</given-names></name><name><surname>Lester</surname><given-names>H.A.</given-names></name></person-group><article-title>The duplicated alpha7 subunits assemble and form functional nicotinic receptors with the full-length alpha7</article-title><source>J. Biol. Chem.</source><year>2014</year></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Ochani</surname><given-names>M.</given-names></name><name><surname>Amella</surname><given-names>C.A.</given-names></name><name><surname>Tanovic</surname><given-names>M.</given-names></name><name><surname>Susarla</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.H.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Ulloa</surname><given-names>L.</given-names></name></person-group><article-title>Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation</article-title><source>Nature</source><volume>421</volume><year>2003</year><fpage>384</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">12508119</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>J.K.</given-names></name><name><surname>Auyeung</surname><given-names>K.K.</given-names></name></person-group><article-title>Inflammatory bowel disease: etiology, pathogenesis and current therapy</article-title><source>Curr. Pharm. Des.</source><volume>20</volume><year>2014</year><fpage>1082</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">23782147</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Molodecky</surname><given-names>N.A.</given-names></name><name><surname>Soon</surname><given-names>I.S.</given-names></name><name><surname>Rabi</surname><given-names>D.M.</given-names></name><name><surname>Ghali</surname><given-names>W.A.</given-names></name><name><surname>Ferris</surname><given-names>M.</given-names></name><name><surname>Chernoff</surname><given-names>G.</given-names></name><name><surname>Benchimol</surname><given-names>E.I.</given-names></name><name><surname>Panaccione</surname><given-names>R.</given-names></name><name><surname>Ghosh</surname><given-names>S.</given-names></name><name><surname>Barkema</surname><given-names>H.W.</given-names></name></person-group><article-title>Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review</article-title><source>Gastroenterology</source><volume>142</volume><issue>46&#x02013;54</issue><year>2012</year><fpage>e42</fpage><comment>(quiz e30)</comment><pub-id pub-id-type="pmid">22001864</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Low</surname><given-names>D.</given-names></name><name><surname>Nguyen</surname><given-names>D.D.</given-names></name><name><surname>Mizoguchi</surname><given-names>E.</given-names></name></person-group><article-title>Animal models of ulcerative colitis and their application in drug research</article-title><source>Drug Des. Devel. Ther.</source><volume>7</volume><year>2013</year><fpage>1341</fpage><lpage>1357</lpage></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Wainszelbaum</surname><given-names>M.J.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Kong</surname><given-names>C.</given-names></name><name><surname>Srikanth</surname><given-names>P.</given-names></name><name><surname>Samovski</surname><given-names>D.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Stahl</surname><given-names>P.D.</given-names></name></person-group><article-title>TBC1D3, a hominoid-specific gene, delays IRS-1 degradation and promotes insulin signaling by modulating p70 S6 kinase activity</article-title><source>PLoS One</source><volume>7</volume><year>2012</year><object-id pub-id-type="publisher-id">e31225</object-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Pfaffl</surname><given-names>M.W.</given-names></name><name><surname>Horgan</surname><given-names>G.W.</given-names></name><name><surname>Dempfle</surname><given-names>L.</given-names></name></person-group><article-title>Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR</article-title><source>Nucleic Acids Res.</source><volume>30</volume><year>2002</year><object-id pub-id-type="publisher-id">e36</object-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Mirza</surname><given-names>A.H.</given-names></name><name><surname>Berthelsen</surname><given-names>C.H.</given-names></name><name><surname>Seemann</surname><given-names>S.E.</given-names></name><name><surname>Pan</surname><given-names>X.</given-names></name><name><surname>Frederiksen</surname><given-names>K.S.</given-names></name><name><surname>Vilien</surname><given-names>M.</given-names></name><name><surname>Gorodkin</surname><given-names>J.</given-names></name><name><surname>Pociot</surname><given-names>F.</given-names></name></person-group><article-title>Transcriptomic landscape of lncRNAs in inflammatory bowel disease</article-title><source>Genome Med.</source><volume>7</volume><year>2015</year><fpage>39</fpage><pub-id pub-id-type="pmid">25991924</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Granlund</surname><given-names>A.</given-names></name><name><surname>Flatberg</surname><given-names>A.</given-names></name><name><surname>Ostvik</surname><given-names>A.E.</given-names></name><name><surname>Drozdov</surname><given-names>I.</given-names></name><name><surname>Gustafsson</surname><given-names>B.I.</given-names></name><name><surname>Kidd</surname><given-names>M.</given-names></name><name><surname>Beisvag</surname><given-names>V.</given-names></name><name><surname>Torp</surname><given-names>S.H.</given-names></name><name><surname>Waldum</surname><given-names>H.L.</given-names></name><name><surname>Martinsen</surname><given-names>T.C.</given-names></name></person-group><article-title>Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e56818</object-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Iboshi</surname><given-names>Y.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>Ihara</surname><given-names>E.</given-names></name><name><surname>Iwasa</surname><given-names>T.</given-names></name><name><surname>Akiho</surname><given-names>H.</given-names></name><name><surname>Harada</surname><given-names>N.</given-names></name><name><surname>Nakamuta</surname><given-names>M.</given-names></name><name><surname>Takayanagi</surname><given-names>R.</given-names></name></person-group><article-title>Multigene analysis unveils distinctive expression profiles of helper T-cell-related genes in the intestinal mucosa that discriminate between ulcerative colitis and Crohn's disease</article-title><source>Inflamm. Bowel Dis.</source><volume>20</volume><year>2014</year><fpage>967</fpage><lpage>977</lpage><pub-id pub-id-type="pmid">24739631</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>van Heel</surname><given-names>D.A.</given-names></name><name><surname>Udalova</surname><given-names>I.A.</given-names></name><name><surname>De Silva</surname><given-names>A.P.</given-names></name><name><surname>McGovern</surname><given-names>D.P.</given-names></name><name><surname>Kinouchi</surname><given-names>Y.</given-names></name><name><surname>Hull</surname><given-names>J.</given-names></name><name><surname>Lench</surname><given-names>N.J.</given-names></name><name><surname>Cardon</surname><given-names>L.R.</given-names></name><name><surname>Carey</surname><given-names>A.H.</given-names></name><name><surname>Jewell</surname><given-names>D.P.</given-names></name></person-group><article-title>Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(&#x02212;&#x000a0;kappa)B transcription factors</article-title><source>Hum. Mol. Genet.</source><volume>11</volume><year>2002</year><fpage>1281</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">12019209</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Vitali</surname><given-names>R.</given-names></name><name><surname>Stronati</surname><given-names>L.</given-names></name><name><surname>Negroni</surname><given-names>A.</given-names></name><name><surname>Di Nardo</surname><given-names>G.</given-names></name><name><surname>Pierdomenico</surname><given-names>M.</given-names></name><name><surname>del Giudice</surname><given-names>E.</given-names></name><name><surname>Rossi</surname><given-names>P.</given-names></name><name><surname>Cucchiara</surname><given-names>S.</given-names></name></person-group><article-title>Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease</article-title><source>Am. J. Gastroenterol.</source><volume>106</volume><year>2011</year><fpage>2029</fpage><lpage>2040</lpage><pub-id pub-id-type="pmid">21788990</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Landback</surname><given-names>P.</given-names></name><name><surname>Gschwend</surname><given-names>A.R.</given-names></name><name><surname>Shen</surname><given-names>B.</given-names></name><name><surname>Long</surname><given-names>M.</given-names></name></person-group><article-title>New genes drive the evolution of gene interaction networks in the human and mouse genomes</article-title><source>Genome Biol.</source><volume>16</volume><year>2015</year><fpage>202</fpage><pub-id pub-id-type="pmid">26424194</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Seok</surname><given-names>J.</given-names></name><name><surname>Warren</surname><given-names>H.S.</given-names></name><name><surname>Cuenca</surname><given-names>A.G.</given-names></name><name><surname>Mindrinos</surname><given-names>M.N.</given-names></name><name><surname>Baker</surname><given-names>H.V.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Richards</surname><given-names>D.R.</given-names></name><name><surname>McDonald-Smith</surname><given-names>G.P.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Hennessy</surname><given-names>L.</given-names></name></person-group><article-title>Genomic responses in mouse models poorly mimic human inflammatory diseases</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>110</volume><year>2013</year><fpage>3507</fpage><lpage>3512</lpage><pub-id pub-id-type="pmid">23401516</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Miyakawa</surname><given-names>T.</given-names></name></person-group><article-title>Genomic responses in mouse models greatly mimic human inflammatory diseases</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>112</volume><year>2015</year><fpage>1167</fpage><lpage>1172</lpage><pub-id pub-id-type="pmid">25092317</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Osuchowski</surname><given-names>M.F.</given-names></name><name><surname>Remick</surname><given-names>D.G.</given-names></name><name><surname>Lederer</surname><given-names>J.A.</given-names></name><name><surname>Lang</surname><given-names>C.H.</given-names></name><name><surname>Aasen</surname><given-names>A.O.</given-names></name><name><surname>Aibiki</surname><given-names>M.</given-names></name><name><surname>Azevedo</surname><given-names>L.C.</given-names></name><name><surname>Bahrami</surname><given-names>S.</given-names></name><name><surname>Boros</surname><given-names>M.</given-names></name><name><surname>Cooney</surname><given-names>R.</given-names></name></person-group><article-title>Abandon the mouse research ship? Not just yet!</article-title><source>Shock</source><volume>41</volume><year>2014</year><fpage>463</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">24569509</pub-id></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Florio</surname><given-names>M.</given-names></name><name><surname>Albert</surname><given-names>M.</given-names></name><name><surname>Taverna</surname><given-names>E.</given-names></name><name><surname>Namba</surname><given-names>T.</given-names></name><name><surname>Brandl</surname><given-names>H.</given-names></name><name><surname>Lewitus</surname><given-names>E.</given-names></name><name><surname>Haffner</surname><given-names>C.</given-names></name><name><surname>Sykes</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>F.K.</given-names></name><name><surname>Peters</surname><given-names>J.</given-names></name></person-group><article-title>Human-specific gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion</article-title><source>Science</source><volume>347</volume><year>2015</year><fpage>1465</fpage><lpage>1470</lpage><pub-id pub-id-type="pmid">25721503</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C.Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Cao</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>P.W.</given-names></name><name><surname>Lu</surname><given-names>S.J.</given-names></name><name><surname>Li</surname><given-names>X.M.</given-names></name><name><surname>Yu</surname><given-names>Q.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name></person-group><article-title>A human-specific de novo protein-coding gene associated with human brain functions</article-title><source>PLoS Comput. Biol.</source><volume>6</volume><year>2010</year><object-id pub-id-type="publisher-id">e1000734</object-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>D.Q.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>J.F.</given-names></name></person-group><article-title>Molecular evolution of the primate alpha&#x000a0;&#x02212;/theta-defensin multigene family</article-title><source>PLoS One</source><volume>9</volume><year>2014</year><object-id pub-id-type="publisher-id">e97425</object-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>F.</given-names></name><name><surname>Springer</surname><given-names>S.A.</given-names></name><name><surname>Altheide</surname><given-names>T.K.</given-names></name><name><surname>Varki</surname><given-names>N.M.</given-names></name><name><surname>Gagneux</surname><given-names>P.</given-names></name><name><surname>Varki</surname><given-names>A.</given-names></name></person-group><article-title>Human-specific derived alleles of CD33 and other genes protect against postreproductive cognitive decline</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>2015</year></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgments</title><p>The authors would like to thank Ms. Emelie Amburn for expert technical assistance and support by the <funding-source id="gts0005">American College of Surgeons C. James Carrico Faculty Research Fellowship (to T.W. Costantini), NIH</funding-source> Grant R01CA170140 (to B.P. Eliceiri), and the <funding-source id="gts0010">Reinvestment Fund of the UC San Diego Division of Trauma, Surgical Critical Care, Burns and Acute Care Surgery</funding-source>.</p></ack></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p>CHRFAM7A and CHRNA7 gene expression in inflammatory bowel disease (IBD). Quantitative RT-PCR was used to measure CHRFAM7A and CHRNA7 gene expression in intestinal biopsies from patients with IBD (panels <italic>A</italic>&#x02013;<italic>C</italic>), ulcerative colitis (panels <italic>D</italic>&#x02013;<italic>F</italic>), and Crohn's disease (panels G&#x02013;J). Gene expression in each sample was normalized to that of actin or, as indicated, between each other to determine the CHRFAM7A/CHRNA7 ratio. Relative gene expression was compared to that in control biopsies using the &#x02206;&#x02206;Ct method. Differences in gene expression between the control and disease biopsies were measured by REST <xref rid="bb0150" ref-type="bibr">[30]</xref> for group-wise comparisons and evaluated as either individual plates and after combination (shown).</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>Changes in CHRFAM7A and CHRNA7 gene expression are specific for IBD. Quantitative RT-PCR was used to measure CHRFAM7A and CHRNA7 gene expression in biopsies of colon cancer (panels <italic>A</italic>&#x02013;<italic>F</italic>) as all biopsies (panels <italic>A</italic>&#x02013;<italic>C</italic>) or by colon cancer stage (panels <italic>D</italic>&#x02013;<italic>F</italic>). Gene expression in each sample was normalized to that of actin or, as indicated, between CHRFAM7A and CHRNA7 using the &#x02206;&#x000a0;Ct method. Relative gene expression was then compared to that in control biopsies using the &#x02206;&#x02206;Ct method. Differences in gene expression between the control and disease biopsies were measured by REST <xref rid="bb0150" ref-type="bibr">[30]</xref> for group-wise comparisons and no differences were found to be significant at p&#x000a0;&#x0003c;&#x000a0;0.05. Expression of the human-specific gene TBCD1 from all IBD samples (panel <italic>G</italic>), in Crohn's and ulcerative colitis (panel <italic>H</italic>) or in colon cancer (panel <italic>I</italic>) were also unchanged. As illustrated in panel <italic>J</italic>, new genes emerge in new environments to adapt to new behaviors like bipedal behavior (trauma) and the harnessing of fire (burn/sepsis) and alter responsiveness. Off-target effects (panel <italic>K</italic>) for example regulating &#x003b1;7-nAChR activity in neurons might prove even more important than the original pro-inflammatory selection but the sequelae for human disease tied to original (inflammation) and unanticipated (mental health) effects of gene expression.</p></caption><graphic xlink:href="gr2"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Tissue biopsies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="left">Ulcerative colitis</th><th align="left">Crohn's disease</th><th colspan="4" align="left">Colon cancer</th></tr></thead><tbody><tr><td align="left"><italic>Array ID</italic></td><td align="center">CCRT101/102</td><td align="center">CCRT101/102</td><td colspan="4" align="center">HCRT104</td></tr><tr><td align="left"><italic>Biopsies studied</italic></td><td align="center">44</td><td align="center">42</td><td colspan="4" align="center">48</td></tr><tr><td align="left">Normal</td><td colspan="2" align="center">11</td><td colspan="4" align="center">8</td></tr><tr><td align="left">Disease</td><td align="center">33</td><td align="center">31</td><td colspan="4" align="center">40</td></tr><tr><td align="left"><italic>Control biopsies</italic></td><td colspan="2"/><td colspan="4"/></tr><tr><td align="left">Location of lesion</td><td colspan="2" align="center">Colon 8</td><td colspan="4" align="center">Colon 8</td></tr><tr><td/><td colspan="2" align="center">Small Intestine 3</td><td colspan="4"/></tr><tr><td align="left"><italic>Gender</italic></td><td colspan="6"/></tr><tr><td align="left">Male</td><td colspan="2" align="center">7</td><td colspan="4" align="center">2</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">4</td><td colspan="4" align="center">6</td></tr><tr><td align="left">Age (years)</td><td colspan="2" align="center">54 (26&#x02013;89)</td><td colspan="4" align="center">78 (60&#x02013;89)</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">56 (26&#x02013;89)</td><td colspan="4" align="center">82 (81&#x02013;82)</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">50 (29&#x02013;70)</td><td colspan="4" align="center">77 (60&#x02013;89)</td></tr><tr><td align="left">% Mucosa</td><td colspan="2" align="center">48% (10&#x02013;90)</td><td colspan="4" align="center">N/A</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">50% (20&#x02013;85)</td><td colspan="4" align="center">N/A</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">44% (10&#x02013;90)</td><td colspan="4" align="center">N/A</td></tr><tr><td align="left"><italic>Disease biopsies</italic></td><td/><td/><td align="center">Tissue</td><td colspan="2" align="center">Stage</td><td align="center">N</td></tr><tr><td align="left">Location of lesion</td><td align="left">Colon 33</td><td align="left">Colon 13</td><td align="center">Colon</td><td colspan="2" align="center">l</td><td align="center">5</td></tr><tr><td/><td align="left">Small Intestine 0</td><td align="left">Small Intestine 18</td><td align="center">Colon</td><td colspan="2" align="center">ll</td><td align="center">9</td></tr><tr><td/><td/><td/><td align="center">Colon</td><td colspan="2" align="center">lll</td><td align="center">16</td></tr><tr><td/><td/><td/><td align="center">Colon</td><td colspan="2" align="center">lV</td><td align="center">10</td></tr><tr><td align="left"><italic>Gender</italic></td><td colspan="6"/></tr><tr><td align="left">Male</td><td align="center">21</td><td align="center">14</td><td colspan="4" align="center">16</td></tr><tr><td align="left">Female</td><td align="center">12</td><td align="center">17</td><td colspan="4" align="center">24</td></tr><tr><td align="left">Age (years)</td><td align="center">39 (22&#x02013;76)</td><td align="center">38 (19&#x02013;65)</td><td colspan="4" align="center">68 (21&#x02013;89)</td></tr><tr><td align="left">Male</td><td align="center">38 (22&#x02013;72)</td><td align="center">40 (20&#x02013;64)</td><td colspan="4" align="center">65 (21&#x02013;82)</td></tr><tr><td align="left">Female</td><td align="center">45 (26&#x02013;76)</td><td align="center">36 (19&#x02013;65)</td><td colspan="4" align="center">70 (45&#x02013;89)</td></tr><tr><td/><td/><td/><td align="center">Well</td><td align="center">Moderate</td><td align="center">Poor</td><td align="center">Un-diff.</td></tr><tr><td align="center">% Mucosa/differentiation*</td><td align="center">43% (10&#x02013;100)</td><td align="center">38 (0&#x02013;00)</td><td align="center">10</td><td align="center">19</td><td align="center">6</td><td align="center">5</td></tr><tr><td align="left">Male</td><td align="center">43% (10&#x02013;100)</td><td align="center">41 (0&#x02013;80)</td><td align="center">7</td><td align="center">11</td><td align="center">4</td><td align="center">2</td></tr><tr><td align="left">Female</td><td align="center">43% (10&#x02013;95)</td><td align="center">35 (10&#x02013;90)</td><td align="center">3</td><td align="center">8</td><td align="center">2</td><td align="center">3</td></tr><tr><td align="left"><italic>Pathology</italic></td><td colspan="6"/></tr><tr><td align="left">Lesion/tumor (%)</td><td colspan="2" align="center">100</td><td colspan="4" align="center">71% (25&#x02013;95%)</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">100</td><td colspan="4" align="center">69.9 (25&#x02013;95)</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">100</td><td colspan="4" align="center">73.7 (40&#x02013;90)</td></tr><tr><td align="left">Hypercellular stroma (%)</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">16% (0&#x02013;55%)</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">17.3 (0&#x02013;55%)</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">14.4 (0&#x02013;35%)</td></tr><tr><td align="left">Hypocellular Stroma (%)</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">1.95% (0&#x02013;28%)</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">2.7 (0&#x02013;28%)</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">N/A</td><td colspan="4" align="center">0.9 (0&#x02013;10%)</td></tr><tr><td align="left">Necrosis (%)</td><td colspan="2" align="center">0</td><td colspan="4" align="center">4.9% (0&#x02013;40%)</td></tr><tr><td align="left">Male</td><td colspan="2" align="center">0</td><td colspan="4" align="center">3.6% (0&#x02013;40%)</td></tr><tr><td align="left">Female</td><td colspan="2" align="center">0</td><td colspan="4" align="center">6.6 (0&#x02013;20%)</td></tr></tbody></table></table-wrap></floats-group></article>